About: Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $125.10 (-1.02%)
PVLA NASDAQ Palvella Therapeutics, Inc
Palvella Therapeutics, Inc share price
Atividade de preço de PVLA
Último preço
$ 125,100
Variação (24h)
-1,29 USD (1,02%)
Volume
161.45K
Volume (média 4 sem.)
-
Abertura
$ 123,50
Variação do dia
$ 121,34 - $ 125,93
Fechamento anterior
$ 126,39
Último negócio
23 Oct, 8:00 pm GMT+0
Atrasado
23 Oct, 8:00 pm GMT+0
PVLA price performance
Atrasado
23 Oct, 8:00 pm GMT+0
quote.marketSignals